Facebook
Twitter
Telegram
Report an ErrorChinook Therapeutics Balance Sheet 2011-2024 | KDNY
Annual Balance Sheet Chinook Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-76 M | -138 M | - | -59.6 M | - | - | - | - | - | - | - | - |
Long Term Debt |
34.5 M | 39.6 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
4.95 M | 4.4 M | 3.04 M | 1.8 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 940 K | - | - | - | - | - | - | - | - |
Total Current Liabilities |
50.8 M | 40.1 M | 22.8 M | 21.6 M | 30.5 M | 41.4 M | 30.6 M | 31.1 M | - | - | - | - |
Total Liabilities |
132 M | 110 M | 94.4 M | 226 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 6.95 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-420 M | -232 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
574 M | 564 M | 429 M | 291 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
115 M | 182 M | 188 M | 59.6 M | 126 M | 158 M | 74.9 M | 150 M | 119 M | 8.53 M | - | - |
Book Value |
442 M | 454 M | 335 M | 65.6 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
442 M | 454 M | 335 M | -41.1 M | 135 M | 237 M | 227 M | 262 M | -61.3 M | -38.8 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Chinook Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
29.7 M | 33.2 M | 34.5 M | 35.8 M | 37.2 M | 38.5 M | 39.6 M | 40.8 M | 37.1 M | 38 M | 38.7 M | 38.7 M | 38.7 M | 38.7 M | 114 K | 31.6 M | 31.6 M | 31.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
132 M | 131 M | 132 M | 116 M | 94.1 M | 104 M | 110 M | 114 M | 111 M | 98.3 M | 94.4 M | 94.4 M | 94.4 M | 94.4 M | 37 M | 226 M | 226 M | 226 M | 222 M | 222 M | 222 M | 222 M | 208 M | 208 M | 208 M | 208 M | 211 M | 211 M | 211 M | 211 M | 220 M | 220 M | 220 M | 220 M | 47.8 M | 47.8 M | 47.8 M | 47.8 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | 95 K | 95 K | 95 K | 95 K | 6.95 M | 16 M | 6.95 M | 6.95 M | 16 M | 16 M | 16 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 15 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 15 M | 15 M | 15 M | 15 M | 33.4 M | 33.4 M | 33.4 M | 33.4 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-547 M | -480 M | -420 M | -357 M | -301 M | -263 M | -232 M | -239 M | -209 M | -166 M | -129 M | -129 M | -129 M | -129 M | -47.2 M | -487 M | -487 M | -487 M | -405 M | -405 M | -405 M | -405 M | -284 M | -284 M | -284 M | -284 M | -192 M | -192 M | -192 M | -192 M | -101 M | -101 M | -101 M | -101 M | -61.6 M | -61.6 M | -61.6 M | -61.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
489 M | 544 M | 574 M | 590 M | 601 M | 531 M | 564 M | 383 M | 408 M | 399 M | 429 M | 429 M | 429 M | 429 M | 15.7 M | 291 M | 291 M | 291 M | 358 M | 358 M | 358 M | 358 M | 445 M | 445 M | 445 M | 445 M | 439 M | 439 M | 439 M | 439 M | 482 M | 482 M | 482 M | 482 M | 126 M | 126 M | 126 M | 126 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
127 M | 118 M | 115 M | 126 M | 146 M | 104 M | 182 M | 109 M | 135 M | 168 M | 190 M | 188 M | 188 M | 188 M | 11.2 M | 59.6 M | 59.6 M | 59.6 M | 126 M | 126 M | 126 M | 126 M | 158 M | 158 M | 158 M | 158 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | 150 M | 150 M | 150 M | 150 M | 119 M | 119 M | 119 M | 119 M | 8.53 M | - | - | - | 3.7 M | - | - | - | - | - | - | - |
Book Value |
357 M | 412 M | 442 M | 475 M | 507 M | 427 M | 454 M | 270 M | 297 M | 301 M | 335 M | 335 M | 335 M | 335 M | -21.3 M | 65.6 M | 65.6 M | 65.6 M | 135 M | 135 M | 135 M | 135 M | 237 M | 237 M | 237 M | 237 M | 227 M | 227 M | 227 M | 227 M | 262 M | 262 M | 262 M | 262 M | 78.7 M | 78.7 M | 78.7 M | 78.7 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
357 M | 412 M | 442 M | 475 M | 507 M | 427 M | 454 M | 270 M | 297 M | 301 M | 335 M | 335 M | 335 M | 335 M | -41.1 M | 65.6 M | 65.6 M | 65.6 M | -681 K | 135 M | 135 M | 135 M | 237 M | 237 M | 237 M | 237 M | 227 M | 227 M | 227 M | 227 M | 262 M | 262 M | 262 M | 262 M | -61.3 M | -61.3 M | -61.3 M | -61.3 M | -38.8 M | - | - | - | -27.7 M | - | - | - | - | - | - | - |
All numbers in USD currency